Cypress Bioscience, Inc. provides therapeutics and personalized medicine services, facilitating individualized patient care. The Company focuses to address the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. In January 2009, the Company received approval from the United States Food and Drug Administration (FDA) to market Savella (milnacipran HCl) for the management of fibromyalgia (FM). On March 4, 2008, Cypress acquired Proprius Pharmaceuticals, Inc. (Proprius), a privately held specialty pharmaceutical company.